Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs
出版年份 2015 全文链接
标题
Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs
作者
关键词
-
出版物
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 55, Issue S3, Pages S4-S20
出版商
Wiley
发表日期
2015-02-24
DOI
10.1002/jcph.407
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension
- (2014) Michie Toba et al. AMERICAN JOURNAL OF PATHOLOGY
- The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
- (2014) Winnie Sohn et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A drug safety evaluation of rituximab and risk of hepatitis B
- (2014) Peter Riedell et al. Expert Opinion On Drug Safety
- Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules
- (2014) Samad Mussa Farkhani et al. PEPTIDES
- Romiplostim for management of chemotherapy-induced thrombocytopenia
- (2014) R. Parameswaran et al. SUPPORTIVE CARE IN CANCER
- Chemically programmed antibodies
- (2014) Christoph Rader TRENDS IN BIOTECHNOLOGY
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
- (2013) Amit Garg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Octreotide
- (2013) Mallory M. Chan et al. CHEST
- Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review
- (2013) Algenes Aranha et al. Endocrine Practice
- Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins
- (2013) A. Richter et al. FEBS LETTERS
- Pharmacokinetics of Peptide–Fc Fusion Proteins
- (2013) W.U. Benjamin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Advances in targeting cell surface signalling molecules for immune modulation
- (2013) Sheng Yao et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody-Based Immunotherapy of Cancer
- (2012) Louis M. Weiner et al. CELL
- A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display
- (2012) A. Koivistoinen et al. Clinical & Translational Oncology
- Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
- (2012) P. A. Tang et al. CLINICAL CANCER RESEARCH
- The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
- (2012) R. J. Boohaker et al. CURRENT MEDICINAL CHEMISTRY
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Pertuzumab
- (2012) Gillian M. Keating DRUGS
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo
- (2012) Ikuhiko Nakase et al. JOURNAL OF CONTROLLED RELEASE
- Targeted drug delivery for cancer therapy: the other side of antibodies
- (2012) Michael A Firer et al. Journal of Hematology & Oncology
- Abstract B237: Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC)
- (2012) P. Woll et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence
- (2012) Ji-Sing Liou et al. PEPTIDES
- Peptides for cell-selective drug delivery
- (2012) Nina Svensen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Integrin Targeted Delivery of Chemotherapeutics
- (2012) Kai Chen et al. Theranostics
- DARTs take aim at BiTEs
- (2011) C. Rader BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
- (2011) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- DARPins and other repeat protein scaffolds: advances in engineering and applications
- (2011) Ykelien L Boersma et al. CURRENT OPINION IN BIOTECHNOLOGY
- Targeted Radiotherapy with Radiolabeled Somatostatin Analogs
- (2011) Guillaume Nicolas et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling
- (2011) Ykelien L. Boersma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold
- (2011) Akiko Koide et al. JOURNAL OF MOLECULAR BIOLOGY
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
- (2011) Stuart L. Emanuel et al. mAbs
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Bispecific Antibodies for Cancer Immunotherapy
- (2010) Dafne Müller et al. BIODRUGS
- A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity
- (2010) P. Martin-Killias et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
- (2010) Bing-Bing Yang et al. CLINICAL PHARMACOKINETICS
- Homing peptides as targeted delivery vehicles
- (2010) Pirjo Laakkonen et al. Integrative Biology
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Approach to the patient after relapse of hairy cell leukemia
- (2010) Robert J. Kreitman et al. LEUKEMIA & LYMPHOMA
- Anti-TNFα domain antibody construct CEP-37247
- (2010) Robert D. Gay et al. mAbs
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold
- (2010) B. J. Hackel et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231
- (2009) Sonia Aroui et al. CANCER LETTERS
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- BiTE: A new class of antibodies that recruit T-cells
- (2009) P.A. Baeuerle et al. DRUGS OF THE FUTURE
- Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
- (2009) N. Yamamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
- (2009) J. Winkler et al. MOLECULAR CANCER THERAPEUTICS
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
- (2008) Sean P Dineen et al. BMC CANCER
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- (2008) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities
- (2008) T. Connerotte et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities
- (2008) Arne Skerra FEBS Journal
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells
- (2008) Christian Kellner et al. JOURNAL OF IMMUNOTHERAPY
- Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling
- (2008) Benjamin J. Hackel et al. JOURNAL OF MOLECULAR BIOLOGY
- Cancer Immunotherapy — The Endgame Begins
- (2008) Louis M. Weiner NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
- (2008) E. A. Dubikovskaya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started